What do systematic reviews say?

LABA/LAMA vs placebo

• Once daily long‐acting beta2‐agonists and long‐acting muscarinic antagonists in a combined inhaler versus placebo for… 2019 · Cochrane Headline outcomes only
  no estimate extracted
  8 studies · 4952 participants
  High

Raloxifene vs placebo

The review found no eligible studies for this question.

• Pharmacological interventions versus placebo, no treatment or usual care for osteoporosis in people with chronic… 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Any anti‐osteoporotic drugs vs placebo

The review found no eligible studies for this question.

• Pharmacological interventions versus placebo, no treatment or usual care for osteoporosis in people with chronic… 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Bisphosphonates vs placebo

The review found no eligible studies for this question.

• Bisphosphonates for osteoporosis in people with cystic fibrosis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Alglucosidase alfa plus clenbuterol vs alglucosidase alfa plus placebo

The review found no eligible studies for this question.

• Enzyme replacement therapy for late‐onset Pompe disease 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Alglucosidase alfa plus albuterol vs alglucosidase alfa plus placebo

The review found no eligible studies for this question.

• Enzyme replacement therapy for late‐onset Pompe disease 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Two or more foetal haemoglobin inducers at any dose or duration vs a usual management protocol, placebo or a single foetal haemoglobin inducer

The review found no eligible studies for this question.

• Foetal haemoglobin inducers for reducing blood transfusion in non‐transfusion‐dependent beta‐thalassaemias 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Single foetal haemoglobin inducer at any dose or duration vs placebo or usual care

The review found no eligible studies for this question.

• Foetal haemoglobin inducers for reducing blood transfusion in non‐transfusion‐dependent beta‐thalassaemias 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Alpha‐blockers vs placebo

The review found no eligible studies for this question.

• Vasodilators for primary Raynaud's phenomenon 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Prostagladin/prostacyclin analogues vs placebo

The review found no eligible studies for this question.

• Vasodilators for primary Raynaud's phenomenon 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Thromboxane synthase inhibitors vs placebo

The review found no eligible studies for this question.

• Vasodilators for primary Raynaud's phenomenon 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Selective serotonin reuptake inhibitors vs placebo

The review found no eligible studies for this question.

• Vasodilators for primary Raynaud's phenomenon 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Nitrate/nitrate derivatives vs placebo

The review found no eligible studies for this question.

• Vasodilators for primary Raynaud's phenomenon 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Angiotensin‐converting enzyme inhibitors vs placebo

The review found no eligible studies for this question.

• Vasodilators for primary Raynaud's phenomenon 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Phosphodiesterase inhibitors vs placebo

The review found no eligible studies for this question.

• Vasodilators for primary Raynaud's phenomenon 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

High‐dose rhGH vs placebo

• Recombinant growth hormone therapy for cystic fibrosis in children and young adults 2021 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 41 participants
  Very low

Standard rhGH vs placebo

• Recombinant growth hormone therapy for cystic fibrosis in children and young adults 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  Very low

Combination therapy vs placebo

• Anticholinergics combined with alpha‐blockers for treating lower urinary tract symptoms related to benign prostatic… 2021 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 991 participants
  Very low

Summary of findings: garlic supplementation vs placebo

The review found no eligible studies for this question.

• Antibiotic adjuvant therapy for pulmonary infection in cystic fibrosis 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings: nitric oxide vs placebo

The review found no eligible studies for this question.

• Antibiotic adjuvant therapy for pulmonary infection in cystic fibrosis 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found